GSK3528869A ± Bepirovirsen Market Size, Forecast, and Emerging Insight - 2032

“GSK3528869A ± Bepirovirsen Market Size, Forecast, and Emerging Insight - 2032” report provides comprehensive insights about GSK3528869A ± Bepirovirsen for chronic hepatitis B in the seven major markets and China. A detailed picture of the GSK3528869A ± Bepirovirsen for chronic hepatitis B in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China for the study period 2019 -2032 is provided in this report along with a detailed description of the GSK3528869A ± Bepirovirsen for chronic hepatitis B. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the GSK3528869A ± Bepirovirsen market forecast analysis for chronic hepatitis B in the 7MM and China, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.

Drug Summary

GSK3228836 (also known as bepirovirsen) is under the developmental process of the collaboration of GlaxoSmithKline (GSK) and Ionis Pharma. It is an investigational antisense oligonucleotide (ASO) designed to specifically recognize the RNA that the hepatitis B virus uses to replicate itself in the infected liver cells (hepatocytes) and make the viral antigens (proteins) that facilitate chronicity of the disease by helping to avoid clearance by the immune system. Bepirovirsen has the additional property of stimulating immune responses via Toll-like receptor 8 (TLR8), which may help the immune system to achieve durable clearance of the virus from circulating blood.

GSK3528869A is a three-component therapeutic vaccine:

• ChAd155-hIi-HBV: replication-defective simian (chimpanzee-derived) Group C adenovirus serotype 155 viral vector encoding sequences of two HBV protein antigens: the truncated hepatitis B core antigen (HBcAg) and the full-length small hepatitis B surface antigen (S-HBsAg)
• MVA-HBV: encoding the above two HBV protein antigens Modified vaccinia Ankara (MVA), which is a highly attenuated vaccinia virus strain
• HBc-HBs/AS01B-4: the above two HBV protein antigens enhanced by the AS01B-4 adjuvant, which is a liposomal combination of 3-O-desacyl-4′-monophosphoryl lipid A (MPL) from Salmonella minnesota and a saponin molecule (QS-21) from plant extract of Quillaja saponaria.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the GSK3528869A ± Bepirovirsen description, mechanism of action, dosage and administration, research and development activities in chronic hepatitis B.
• Elaborated details on GSK3528869A ± Bepirovirsen regulatory milestones and other development activities have been provided in this report.
• The report also highlights the GSK3528869A ± Bepirovirsen research and development activities in chronic hepatitis B across the United States, Europe, Japan, and China.
• The report also covers the patents information with expiry timeline around GSK3528869A ± Bepirovirsen.
• The report contains forecasted sales of GSK3528869A ± Bepirovirsen for chronic hepatitis B till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic hepatitis B.
• The report also features the SWOT analysis with analyst views for GSK3528869A ± Bepirovirsen in chronic hepatitis B.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

GSK3528869A ± Bepirovirsen Analytical Perspective

In-depth GSK3528869A ± Bepirovirsen Market Assessment

This report provides a detailed market assessment of GSK3528869A ± Bepirovirsen for chronic hepatitis B in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China. This segment of the report provides forecasted sales data from 2029 to 2032.

GSK3528869A ± Bepirovirsen Clinical Assessment

The report provides the clinical trials information of GSK3528869A ± Bepirovirsen for chronic hepatitis B covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for chronic hepatitis B is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence GSK3528869A ± Bepirovirsen dominance.
• Other emerging products for chronic hepatitis B are expected to give tough market competition to GSK3528869A ± Bepirovirsen and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of GSK3528869A ± Bepirovirsen in chronic hepatitis B.
• Our in-depth analysis of the forecasted sales data of GSK3528869A ± Bepirovirsen from 2029 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the GSK3528869A ± Bepirovirsen in chronic hepatitis B.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of GSK3528869A ± Bepirovirsen?
• What is the clinical trial status of the study related to GSK3528869A ± Bepirovirsen in chronic hepatitis B and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the GSK3528869A ± Bepirovirsen development?
• What are the key designations that have been granted to GSK3528869A ± Bepirovirsen for chronic hepatitis B?
• What is the forecasted market scenario of GSK3528869A ± Bepirovirsen for chronic hepatitis B?
• What are the forecasted sales of GSK3528869A ± Bepirovirsen in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China?
• What are the other emerging products available and how are these giving competition to GSK3528869A ± Bepirovirsen for chronic hepatitis B?
• Which are the late-stage emerging therapies under development for the treatment of chronic hepatitis B?

This product will be delivered within 2 business days.